A.22 PD-1 / PD-L1 immune checkpoint inhibitors – multiple cancers
Application, expert reviews and public comments
Application
Cancer experts consultation report
Comments
WHO department comments
Supporting documents
The documents below were developed by the Secretariat and informed by the application, literature searches, and pricing data provided by the WHO Health Technology Access Management team.
A.22 Biliary tract cancer - EtD framework
A.22 Cervical cancer - EtD framework
A.22 Colorectal cancer - EtD framework
A.22 Endometrial cancer - EtD framework
A.22 Esophageal squamous cell cancer - EtD framework
A.22 Gastric or gastro-esophageal junction adenocarcinoma - EtD framework
A.22 Hepatocellular carcinoma - EtD framework
A.22 Head and neck squamous cell carcinoma - EtD framework
A.22 Malignant melanoma - EtD framework
A.22 Non-small cell lung cancer with high expression of PDL1 - EtD framework
A.22 Non-small cell lung cancer irrespective of PDL1 expression - EtD framework